CAS 835872-35-0
:L-Leucine, L-phenylalanyl-L-cysteinyl-L-isoleucylglycyl-L-arginyl-
Description:
The chemical substance with the name "L-Leucine, L-phenylalanyl-L-cysteinyl-L-isoleucylglycyl-L-arginyl-" and CAS number 835872-35-0 is a peptide composed of several amino acids, including L-leucine, L-phenylalanine, L-cysteine, L-isoleucine, glycine, and L-arginine. This compound is characterized by its sequence of amino acids, which contributes to its unique properties and biological functions. Peptides like this one can exhibit various activities, including roles in signaling, metabolism, and cellular functions. The presence of sulfur in cysteine allows for the formation of disulfide bonds, which can stabilize the peptide's structure. Additionally, the hydrophobic nature of leucine and isoleucine can influence the peptide's interactions with membranes and proteins. The overall charge and polarity of the peptide are determined by the side chains of the amino acids, affecting its solubility and reactivity in biological systems. Such peptides are often studied for their potential therapeutic applications and roles in nutrition and biochemistry.
Formula:C32H53N9O7S
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 3 products.
L-Phenylalanyl-L-cysteinyl-L-isoleucylglycyl-L-arginyl-L-leucine
CAS:<p>L-Phenylalanyl-L-cysteinyl-L-isoleucylglycyl-L-arginyl-L-leucine</p>Purity:97%Molecular weight:707.9g/molAT-1002
CAS:<p>AT-1002 is a tight junction regulator and absorption enhancer. It is a 6-mer synthetic peptide.</p>Formula:C32H53N9O7SPurity:98%Color and Shape:SolidMolecular weight:707.88AT1002
CAS:<p>AT1002 is a small molecule that has been shown to have both cytotoxic and genotoxic activity. It interacts with the voltage-gated sodium channels in the membrane of cancer cells, which leads to increased intracellular calcium levels. This causes significant cytotoxicity in breast cancer cells (MDA-MB-231) and other cancer cell lines. AT1002 also inhibits the growth of infectious pathogens by inhibiting their protein synthesis. AT1002 may be used as a therapeutic agent for inflammatory bowel disease, due to its ability to inhibit the release of proinflammatory cytokines from macrophages.<br>AT1002 has been found to have no significant toxicity in animal studies and does not cause oxidative injury or DNA damage. It does not induce brain function disorders, such as cognitive impairment or seizures, nor does it affect brain function through mitochondrial dysfunction or oxidative injury. AT1002 also does not cause changes in blood pressure or heart rate that would be indicative of autonomic nervous system</p>Formula:C32H53N9O7SPurity:Min. 95%Molecular weight:707.9 g/mol
